EA201491727A1 - Способ лечения рака с применением ингибиторов киназы аврора - Google Patents

Способ лечения рака с применением ингибиторов киназы аврора

Info

Publication number
EA201491727A1
EA201491727A1 EA201491727A EA201491727A EA201491727A1 EA 201491727 A1 EA201491727 A1 EA 201491727A1 EA 201491727 A EA201491727 A EA 201491727A EA 201491727 A EA201491727 A EA 201491727A EA 201491727 A1 EA201491727 A1 EA 201491727A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treating cancer
kinase inhibitors
aurora kinase
disclosed
methods
Prior art date
Application number
EA201491727A
Other languages
English (en)
Other versions
EA036434B1 (ru
Inventor
Ариджит Чакраварти
Джеффри А. Эксиди
Роберт В. Клейнфилд
Кха Н. Ли
Вен Чуи Шю
Картхик Венкатакришнан
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201491727A1 publication Critical patent/EA201491727A1/ru
Publication of EA036434B1 publication Critical patent/EA036434B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Раскрыты способы лечения разных клеточных пролиферативных нарушений. Раскрыты, в частности, способы лечения разных клеточных пролиферативных нарушений путем введения селективного ингибитора киназы Аврора А в комбинации с химиотерапией таксанами, такими как паклитаксел или доцетаксел.
EA201491727A 2012-03-20 2013-03-19 Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела EA036434B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (en) 2012-03-20 2013-03-19 Methods of treating cancer using aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201491727A1 true EA201491727A1 (ru) 2015-01-30
EA036434B1 EA036434B1 (ru) 2020-11-10

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491727A EA036434B1 (ru) 2012-03-20 2013-03-19 Способ лечения рака легких с применением комбинации ингибитора киназы аврора и паклитаксела

Country Status (25)

Country Link
US (2) US20130303519A1 (ru)
EP (1) EP2827855B1 (ru)
JP (1) JP6373252B2 (ru)
KR (1) KR102128866B1 (ru)
CN (1) CN104271129A (ru)
AU (1) AU2013235275B2 (ru)
CA (1) CA2868024A1 (ru)
EA (1) EA036434B1 (ru)
ES (1) ES2746946T3 (ru)
GE (1) GEP20186900B (ru)
HK (1) HK1206253A1 (ru)
IL (1) IL234686B (ru)
IN (1) IN2014DN08477A (ru)
JO (1) JO3630B1 (ru)
MA (1) MA37438A1 (ru)
MX (1) MX358411B (ru)
MY (1) MY175225A (ru)
NZ (1) NZ700744A (ru)
PH (1) PH12014502109A1 (ru)
SG (2) SG10201607741RA (ru)
TN (1) TN2014000387A1 (ru)
TW (1) TWI649082B (ru)
UA (1) UA117455C2 (ru)
WO (1) WO2013142491A1 (ru)
ZA (1) ZA201407551B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2774952C2 (ru) * 2017-06-02 2022-06-24 Ф. Хоффманн-Ля Рош Аг Соединения

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
JP2018502089A (ja) * 2014-12-23 2018-01-25 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒａｆ阻害剤及びａｕｒｏｒａキナーゼ阻害剤の組み合わせ
EP3317427B1 (en) * 2015-07-02 2020-12-23 Millennium Pharmaceuticals, Inc. Biomarkers of response to selective inhibitors of aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
IL59316A (en) 1979-02-07 1983-07-31 Sparamedica Ag Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IL126095A0 (en) 1996-03-08 1999-05-09 Zeneca Ltd Azolobenzazepine derivatives as neurogically active agents
US6057329A (en) 1996-12-23 2000-05-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
ATE233764T1 (de) 1997-09-29 2003-03-15 Meiji Seika Kaisha Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
CA2422371C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US20030105090A1 (en) 2000-12-21 2003-06-05 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
CN100418955C (zh) 2001-08-09 2008-09-17 埃科特莱茵药品有限公司 新型苯并稠杂环
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
MXPA06013042A (es) 2004-05-14 2007-02-12 Millennium Pharm Inc Compuestos y m??todos para inhibir la progresion mit??tica.
WO2006055831A2 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
MX2008008320A (es) 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
BRPI0621024A2 (pt) 2006-01-16 2011-11-29 Jubilant Organosys Ltd formulação farmacêutica estável de um composto de ácido lábil e o processo para preparação do mesmo
WO2008020314A2 (en) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Statin stabilizing dosage formulations
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CA2668267A1 (en) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Elvucitabine pharmaceutical compositions
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
PE20081891A1 (es) 2007-03-22 2008-12-27 Opko Health Inc Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
US20110033461A1 (en) * 2008-03-12 2011-02-10 Vladimir Ratushny Combination Therapy for the Treatment of Cancer
BRPI0914630A2 (pt) 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2774952C2 (ru) * 2017-06-02 2022-06-24 Ф. Хоффманн-Ля Рош Аг Соединения

Also Published As

Publication number Publication date
PH12014502109A1 (en) 2014-12-10
MA37438A1 (fr) 2016-05-31
ZA201407551B (en) 2019-01-30
JP2015510945A (ja) 2015-04-13
US20160193224A1 (en) 2016-07-07
MY175225A (en) 2020-06-16
KR102128866B1 (ko) 2020-07-01
IL234686B (en) 2020-01-30
WO2013142491A1 (en) 2013-09-26
EP2827855A1 (en) 2015-01-28
TW201343169A (zh) 2013-11-01
TN2014000387A1 (en) 2015-12-21
KR20140144215A (ko) 2014-12-18
GEP20186900B (en) 2018-10-10
MX358411B (es) 2018-08-20
US10213436B2 (en) 2019-02-26
EP2827855B1 (en) 2019-06-26
SG10201607741RA (en) 2016-11-29
MX2014011324A (es) 2014-12-05
NZ700744A (en) 2016-09-30
AU2013235275B2 (en) 2017-12-07
CN104271129A (zh) 2015-01-07
JP6373252B2 (ja) 2018-08-15
JO3630B1 (ar) 2020-08-27
IN2014DN08477A (ru) 2015-05-08
UA117455C2 (uk) 2018-08-10
SG11201405621UA (en) 2014-10-30
IL234686A0 (en) 2014-11-30
US20130303519A1 (en) 2013-11-14
HK1206253A1 (en) 2016-01-08
ES2746946T3 (es) 2020-03-09
CA2868024A1 (en) 2013-09-26
AU2013235275A1 (en) 2014-10-23
TWI649082B (zh) 2019-02-01
EA036434B1 (ru) 2020-11-10

Similar Documents

Publication Publication Date Title
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
PH12017501999A1 (en) K-ras modulators
PL2922828T3 (pl) Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
CL2015002932A1 (es) Inhibidores de proteína quinasa
HK1249469A1 (zh) 用RORγ抑制劑治療癌症的方法
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
EA201791133A1 (ru) Ингибиторы erk
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
CL2015000092A1 (es) Oligonucleótidos quiralmente controlados, composición que los comprende; método de elaboración: y uso para tratar cáncer.
MX355728B (es) Inhibidores de cinasas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
WO2012135641A3 (en) Aurora kinase inhibitors and methods of making and using thereof
EP3252019A4 (en) Method for treating wastewater, and activator for treating wastewater
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CL2016001218A1 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
WO2014197885A3 (en) Inhibitors of complement factor h
IN2014CN04050A (ru)
BR112013033674A2 (pt) composições, métodos e kits para tratamento da leucemia
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
MX2015013021A (es) 5-bromo-indirrubinas.
CO6910192A2 (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de pi3kbeta y el inhibidor de la vía de map, incluídos los inhibidores de mek y raf
EA201491727A1 (ru) Способ лечения рака с применением ингибиторов киназы аврора
WO2016054237A3 (en) Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
MX369674B (es) Monolitos con compuestos de reconocimiento unidos, arreglos de los mismos y usos de los mismos.
BR112015022576A2 (pt) produto farmacêutico e seu uso, kit e método para tratar uma disfunção hiperproliferativa

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU